Cliff Asness’s Lunai Bioworks LNAI Stock Holding History

Cliff Asness’s Portfolio LNAI Stock Details LNAI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-130	Closed	-$3.01K	–	3568
2025 Q2	$3.01K	Sell	130 -120	-48%	-$3.35K	﹤0.01%	3292
2025 Q1	$10.9K	Buy	250 +119	+91%	+$7.62K	﹤0.01%	3144
2024 Q4	$8.76K	Buy	+131	New	+$8.69K	﹤0.01%	2856
2023 Q1	–	Sell	-260	Closed	-$21.4K	–	2239
2022 Q4	$21.4K	Sell	260 -63	-20%	-$8.46K	﹤0.01%	2181
2022 Q3	$47K	Buy	+323	New	+$58.9K	﹤0.01%	2150

Other funds holding LNAI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Cliff Asness's LNAI Position: Q3 2025 in Review

Cliff Asness sold out of Lunai Bioworks (LNAI) in Q3 2025, closing a stake of 130 shares — an estimated $3.01K sold.

Cliff Asness first reported a position in LNAI in Q3 2022 and held it in 5 quarters. The position peaked at $47K in Q3 2022. 20 funds tracked by Wall St. Rank hold LNAI as of Q3 2025.

Cliff Asness reported no remaining Lunai Bioworks position as of Q3 2025 after selling out during the quarter.
Cliff Asness sold 130 Lunai Bioworks shares in Q3 2025, an estimated $3.01K.
Cliff Asness first reported a position in Lunai Bioworks in Q3 2022 and held it in 5 quarters.
Cliff Asness's Lunai Bioworks position peaked at $47K in Q3 2022.
20 funds tracked by Wall St. Rank held Lunai Bioworks as of Q3 2025.

Based on AQR Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.